Loading organizations...
AffaMed Therapeutics is a clinical-stage biopharmaceutical company developing treatments for ophthalmic, neurological, and psychiatric disorders, based in Shanghai, China. The organization operates through a research, development, and licensing model, acquiring regional and global rights to promising late-stage drug candidates to address critical unmet medical needs across Greater China and international markets. Led by former Pfizer and BeiGene executives, the enterprise has raised over $170 million in Series B financing to support its clinical pipeline and commercialization efforts. This funding was supported by a syndicate of prominent institutional investors, including KKR, Lake Bleu Capital, and OrbiMed. The company recently advanced its portfolio by securing commercialization approval for the ophthalmic insert DEXTENZA in Macau and initiating clinical trials for its retinal disease treatment AM712. AffaMed Therapeutics was founded in 2019 by the healthcare-focused private equity firm CBC Group.
AffaMed Therapeutics has raised $170.0M across 1 funding round.
AffaMed Therapeutics has raised $170.0M in total across 1 funding round.
AffaMed Therapeutics has raised $170.0M across 1 funding round. Most recently, it raised $170.0M Series B in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 30, 2021 | $170M Series B | BIN LI | WEI FU, Fountainhead Partners, Orion Science Capital, Partners Investment, Superstring Capital | Announced |
AffaMed Therapeutics has raised $170.0M in total across 1 funding round.
AffaMed Therapeutics's investors include Bin Li, Wei Fu, Fountainhead Partners, Orion Science Capital, Partners Investment, Superstring Capital.
